Validation Data Gallery
Tested Applications
Positive WB detected in | A549 cells, HeLa cells, MCF-7 cells |
Positive IF/ICC detected in | MCF-7 cells |
Recommended dilution
Application | Dilution |
---|---|
Western Blot (WB) | WB : 1:1000-1:4000 |
Immunofluorescence (IF)/ICC | IF/ICC : 1:400-1:1600 |
It is recommended that this reagent should be titrated in each testing system to obtain optimal results. | |
Sample-dependent, Check data in validation data gallery. |
Product Information
32103-1-AP targets BCL9L in WB, IF/ICC, ELISA applications and shows reactivity with human samples.
Tested Reactivity | human |
Host / Isotype | Rabbit / IgG |
Class | Polyclonal |
Type | Antibody |
Immunogen | BCL9L fusion protein Ag36794 相同性解析による交差性が予測される生物種 |
Full Name | B-cell CLL/lymphoma 9-like |
Calculated molecular weight | 157 kDa |
Observed molecular weight | 220 kDa |
GenBank accession number | NM_182557 |
Gene Symbol | BCL9L |
Gene ID (NCBI) | 283149 |
RRID | AB_3670192 |
Conjugate | Unconjugated |
Form | Liquid |
Purification Method | Antigen affinity Purification |
UNIPROT ID | Q86UU0 |
Storage Buffer | PBS with 0.02% sodium azide and 50% glycerol , pH 7.3 |
Storage Conditions | Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage. |
Background Information
B-cell CLL/lymphoma 9-like protein (BCL9L, also known as B9L, BCL9-2, and DLNB11) is a transcriptional regulator that acts as an activator, which locates in nucleolus and nucleoplasm (PMID: 33767438). It is predicted to be implicated in the WNT-β-catenin signaling pathway to regulate the progress of hepatocellular carcinoma, breast cancer, and colon cancer (PMID: 31440992; 34545187; 30698996).
Protocols
Product Specific Protocols | |
---|---|
WB protocol for BCL9L antibody 32103-1-AP | Download protocol |
IF protocol for BCL9L antibody 32103-1-AP | Download protocol |
Standard Protocols | |
---|---|
Click here to view our Standard Protocols |